Kang Eungu, Suh Jin Kyung, Kim Sang-Dae
Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Korean Neurosurg Soc. 2025 May;68(3):294-304. doi: 10.3340/jkns.2025.0024. Epub 2025 Apr 29.
Constitutional mismatch repair deficiency (CMMRD) is a rare and highly aggressive cancer predisposition syndrome caused by biallelic germline mutations in mismatch repair genes. This condition is characterized by early-onset malignancies across multiple organ systems, including central nervous system tumors, hematological cancers, and gastrointestinal malignancies. CMMRD-associated tumors exhibit hypermutation and microsatellite instability, resulting in a high tumor mutation burden and rendering these malignancies responsive to immune checkpoint inhibitors (ICIs). ICIs targeting programmed cell death protein-1 and programmed cell death ligand 1 have demonstrated remarkable efficacy, particularly in hypermutated tumors, providing durable responses and improving survival outcomes. Advances in genetic and molecular diagnostics have enhanced the ability to identify CMMRD early, allowing for the implementation of comprehensive surveillance programs and improved management strategies. A multidisciplinary and individualized approach is essential for managing CMMRD patients. This review underscores the importance of early diagnosis, surveillance, and emerging therapeutic approaches to improve outcomes and quality of life for individuals and families affected by this devastating syndrome.
遗传性错配修复缺陷(CMMRD)是一种罕见且侵袭性很强的癌症易感综合征,由错配修复基因的双等位基因种系突变引起。这种病症的特征是多个器官系统出现早发性恶性肿瘤,包括中枢神经系统肿瘤、血液系统癌症和胃肠道恶性肿瘤。与CMMRD相关的肿瘤表现出高突变率和微卫星不稳定性,导致肿瘤突变负荷高,并使这些恶性肿瘤对免疫检查点抑制剂(ICI)敏感。靶向程序性细胞死亡蛋白1和程序性细胞死亡配体1的ICI已显示出显著疗效,尤其是在高突变肿瘤中,能提供持久反应并改善生存结果。遗传和分子诊断技术的进步提高了早期识别CMMRD的能力,从而能够实施全面的监测计划并改进管理策略。多学科和个体化方法对于管理CMMRD患者至关重要。本综述强调了早期诊断、监测和新兴治疗方法对于改善受这种毁灭性综合征影响的个人和家庭的结局及生活质量的重要性。